GSK to buy Human Genome Sciences
GlaxoSmithKline plans to acquire Human Genome Sciences (HGS) in a cash deal of about $3 billion. GSK said Monday that the purchase of HGS will give the company full ownership of the medications Benlysta (lupus), albiglutide (type 2 diabetes) and darapladib (coronary heart disease).